BRKR Stock Recent News

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced preliminary revenue for the first quarter ended March 31, 2025, in a range of $795 million to $800 million, comparing favorably to the Company's earlier outlook and well ahead of consensus. This estimated range implies reported revenue growth of approximately 10% year-over-year, with low-double digit percentage constant exchange rate revenue growth. Bruker estimates non-GAAP organic revenue growth in the first.

VIENNA--(BUSINESS WIRE)---- $BRKR #BRKR--At the ESCMID Global 2025 conference, Bruker´s Microbiology and Infection Diagnostics division is announcing the expansion of its microbiology solutions into Next-Generation Sequencing (NGS) applications, with new, research-use only NGS-based solutions in epidemiology and hospital acquired infection (HAI) tracing. Bruker has entered into a strategic collaboration for NGS bioinformatics applications in microbiology and infectious disease testing with Ridom GmbH, based in.

BRKR's new 1.3 GHz high-resolution NMR system comes with a stable, standard-bore 54 mm superconducting magnet.

ASILOMAR, Calif.--(BUSINESS WIRE)---- $BRKR #BRKR--At the Joint ENC-ISMAR Conference 2025, Bruker Corporation, the leading provider of Nuclear Magnetic Resonance (NMR) spectroscopy solutions, announced the successful development and testing of the world's first high-resolution 1.3 GHz NMR spectrometer with a stable, standard-bore 54 mm superconducting magnet. This first-of-a-kind ultra-high field magnet and spectrometer pushes the boundaries of what is possible in the field of NMR research and opens a new chap.

ASILOMAR, Calif.--(BUSINESS WIRE)---- $BRKR #BRKR--At the Joint ENC-ISMAR Conference 2025, Bruker Corporation, the leading provider of Nuclear Magnetic Resonance (NMR) spectroscopy solutions, announced the launch of an innovative Fourier 80 multinuclear benchtop FT-NMR spectrometer, known as the ‘Multi-Talent' configuration. This novel Fourier 80 ‘Multi-Talent' system represents a major advancement in permanent magnet-based FT-NMR technology, as its unique, next-generation capabilities meet the evolving needs.

Citi lowered the firm's price target on Bruker to $50 from $75 and keeps a Buy rating on the shares as part of a Q1 preview for the life science tools and diagnostics group. The firm believes tariffs and the National Institutes of Health spending cuts are overhands on the sector. 30 May

BRKR announces first successful customer installation of novel d-DNP Polarizer at UCSF.

SAN FRANCISCO--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation today announced the introduction of its groundbreaking dissolution Dynamic Nuclear Polarization (d-DNP) Polarizer at the 2025 Hyperpolarized Carbon-13 MRI Technology Development Workshop at the University of California San Francisco (UCSF) Hyperpolarized MRI Technology Resource Center. The first customer installation of this innovative technology has been successfully completed, marking a milestone in hyperpolarized MRI for preclinical research.

BRKR unveils X4 POSEIDON advanced XRM for 3D microscopy in industrial and scientific applications.

KONTICH, Belgium--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announces the launch of the new X4 POSEIDON™, a high-performance 3D X-ray microscope (XRM) using micro-Computed Tomography (microCT). This innovative benchtop XRM system offers advanced capabilities comparable to larger, floor-standing systems to make high-resolution 3D X-ray microscopy accessible for demanding XRM applications in industrial applications and scientific research. The X4 POSEIDON features a high-end X-ray.